May 31, 2022 02:17 PM EDTUpdated 04:23 PM
Pharma
Law

J&J takes Au­robindo to court over po­ten­tial Er­lea­da gener­ic

Nicole DeFeudis

Editor

Since snag­ging a first ap­proval in prostate can­cer back in 2018, John­son & John­son has been work­ing to make Er­lea­da a block­buster fran­chise. Now that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times